	US 11,833,199 B2
	Peptide fragments from filoviruses and their uses
Surender Khurana, Clarksburg, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Silver Spring, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Silver Spring, MD (US)
Filed on Nov. 16, 2021, as Appl. No. 17/527,968.
Application 17/527,968 is a continuation of application No. 16/346,009, granted, now 11,202,824, previously published as PCT/US2017/059407, filed on Oct. 31, 2017.
Claims priority of provisional application 62/414,960, filed on Oct. 31, 2016.
Prior Publication US 2022/0072119 A1, Mar. 10, 2022
Int. Cl. A61K 39/12 (2006.01); C07K 14/005 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/12 (2013.01) [C07K 14/005 (2013.01); G01N 33/56983 (2013.01); A61K 2039/6081 (2013.01); C12N 2760/14122 (2013.01); C12N 2760/14134 (2013.01); G01N 2469/20 (2013.01); G01N 2800/26 (2013.01)]

12 Claims

1. A method for generating an immune response to ebolavirus glycoprotein (GP) in a subject, comprising administering to the subject an effective amount of a peptide to generate the immune response, wherein the peptide comprises an amino acid sequence set forth as SEQ ID NO: 3, and wherein the peptide is no more than 40 amino acids in length.